dc.contributor.author | Nieder, Carsten | |
dc.contributor.author | Dalhaug, Astrid | |
dc.contributor.author | Haukland, Ellinor Christin | |
dc.date.accessioned | 2022-03-09T13:05:54Z | |
dc.date.available | 2022-03-09T13:05:54Z | |
dc.date.issued | 2021-08-16 | |
dc.description.abstract | Background and aim: The prognostic assessment of patients referred for palliative radiotherapy can be conducted by sitespecific scores. A quick assessment that would cover the whole spectrum could simplify the working day of clinicians who are not specialists for a particular disease site. This study evaluated a promising score, the LabBM (validated for brain metastases), in patients treated for other indications.<p> <p>Materials and methods: The LabBM score was calculated in 375 patients by assigning 1 point each for C-reactive protein and lactate dehydrogenase above the upper limit of normal, and 0.5 points each for hemoglobin, platelets and albumin below the lower limit of normal. Uni- and multivariate analyses were performed.<p> Results: Median overall survival gradually decreased with increasing point sum (range 25.1–1.1 months). When grouped according to the original three-tiered model, excellent discrimination was found. Patients with 0–1 points had a median survival of 15.7 months. Those with 1.5–2 points had a median survival of 5.8 months. Finally, those with 2.5–3.5 points had a median survival of 3.2 months (all p-values ≤ 0.001).<p> Conclusion: The LabBM score, which is derived from inexpensive blood tests and easy to use, stratified patients into three very distinct prognostic groups and deserves further validation. | en_US |
dc.identifier.citation | Nieder C, Dalhaug A, Haukland E. The LabBM score is an excellent survival prediction tool in patients undergoing palliative radiotherapy. Reports of Practical Oncology and Radiotherapy. 2021;26(5):740-746 | en_US |
dc.identifier.cristinID | FRIDAID 1966926 | |
dc.identifier.doi | 10.5603/RpOR.a2021.0096 | |
dc.identifier.issn | 1507-1367 | |
dc.identifier.issn | 2083-4640 | |
dc.identifier.uri | https://hdl.handle.net/10037/24355 | |
dc.language.iso | eng | en_US |
dc.publisher | Via Medica | en_US |
dc.relation.journal | Reports of Practical Oncology and Radiotherapy | |
dc.rights.accessRights | openAccess | en_US |
dc.rights.holder | Copyright 2021 Greater Poland Cancer Centre | en_US |
dc.title | The LabBM score is an excellent survival prediction tool in patients undergoing palliative radiotherapy | en_US |
dc.type.version | publishedVersion | en_US |
dc.type | Journal article | en_US |
dc.type | Tidsskriftartikkel | en_US |
dc.type | Peer reviewed | en_US |